Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 2.75
NAS:OCRX's Cash-to-Debt is ranked lower than
67% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:OCRX: 2.75 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:OCRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.68  Med: 4.56 Max: No Debt
Current: 2.75
Equity-to-Asset 0.53
NAS:OCRX's Equity-to-Asset is ranked lower than
66% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:OCRX: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:OCRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.09  Med: 0.6 Max: 0.96
Current: 0.53
-1.09
0.96
Piotroski F-Score: 3
Altman Z-Score: -9.93
Beneish M-Score: -0.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -4111.66
NAS:OCRX's Operating Margin % is ranked lower than
89% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:OCRX: -4111.66 )
Ranked among companies with meaningful Operating Margin % only.
NAS:OCRX' s Operating Margin % Range Over the Past 10 Years
Min: -19801.5  Med: -5209.25 Max: -63.42
Current: -4111.66
-19801.5
-63.42
Net Margin % -4279.80
NAS:OCRX's Net Margin % is ranked lower than
89% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. NAS:OCRX: -4279.80 )
Ranked among companies with meaningful Net Margin % only.
NAS:OCRX' s Net Margin % Range Over the Past 10 Years
Min: -20604.71  Med: -5263.59 Max: -85.5
Current: -4279.8
-20604.71
-85.5
ROE % -134.69
NAS:OCRX's ROE % is ranked lower than
84% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:OCRX: -134.69 )
Ranked among companies with meaningful ROE % only.
NAS:OCRX' s ROE % Range Over the Past 10 Years
Min: -236.08  Med: -89.59 Max: -49.17
Current: -134.69
-236.08
-49.17
ROA % -77.59
NAS:OCRX's ROA % is ranked lower than
78% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. NAS:OCRX: -77.59 )
Ranked among companies with meaningful ROA % only.
NAS:OCRX' s ROA % Range Over the Past 10 Years
Min: -230.64  Med: -64.59 Max: -15.31
Current: -77.59
-230.64
-15.31
ROC (Joel Greenblatt) % -37555.72
NAS:OCRX's ROC (Joel Greenblatt) % is ranked lower than
95% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. NAS:OCRX: -37555.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:OCRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -46351.52  Med: -4243.35 Max: -526.49
Current: -37555.72
-46351.52
-526.49
3-Year Revenue Growth Rate 26.00
NAS:OCRX's 3-Year Revenue Growth Rate is ranked higher than
78% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:OCRX: 26.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:OCRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -48.65 Max: 26
Current: 26
0
26
3-Year EBITDA Growth Rate -21.60
NAS:OCRX's 3-Year EBITDA Growth Rate is ranked lower than
76% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. NAS:OCRX: -21.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:OCRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -67.65 Max: -21.6
Current: -21.6
3-Year EPS without NRI Growth Rate -21.50
NAS:OCRX's 3-Year EPS without NRI Growth Rate is ranked lower than
73% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:OCRX: -21.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:OCRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -69.15 Max: -21.5
Current: -21.5
GuruFocus has detected 3 Warning Signs with Ocera Therapeutics Inc $NAS:OCRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:OCRX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:EMIS, OTCPK:DDRT, NAS:VICL, AMEX:CRMD, OTCPK:PXRB, NAS:PTIE, OTCPK:BIOAF, NAS:THLD, NAS:EARS, OTCPK:RGRX, OTCPK:BLEVF, OTCPK:IPATF, NAS:VKTX, NAS:CSBR, OTCPK:BNHLF, NAS:DMPI, NAS:ONS, NAS:MIRN, AMEX:CANF, OTCPK:KBIO » details
Traded in other countries:6TY1.Germany,
Headquarter Location:USA
Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of proprietary compounds to treat acute and chronic orphan liver disease.

Ocera Therapeutics Inc was incorporated in Delaware on December 20, 2004. The Company is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of OCR-002 for the treatment of hepatic encephalopathy or HE. OCR-002 is a novel molecule, ornithine phenylacetate, which functions as an ammonia scavenger. In pre-clinical studies, OCR-002 reduced arterial ammonia in an animal model of chronic liver disease and reduced arterial ammonia, brain ammonia and intracranial pressure in a second animal model of acute liver failure. OCR-002 has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration, or FDA, for the treatment of hyperammonemia and resultant HE in patients with acute liver failure and acute-on-chronic liver disease. OCR-002 has also been granted orphan drug designation in the European Union for the treatment of acute liver failure. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat HE. The Company is subject to federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Top Ranked Articles about Ocera Therapeutics Inc

Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2
Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update
Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017
Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)
Ocera to Present at the 16th Annual Needham Healthcare Conference

-- Company Presentation Scheduled for April 4, 2017 at 4:20 PM ET --

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 27, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Michael Byrnes, Chief Financial Officer, will be presenting at the upcoming 16th Annual Needham Healthcare Conference being held April 4-5, 2017 at The Westin Grand Central in New York, New York. Ocera’s presentation will take place on April 4, 2017 at 4:20 PM Eastern Time. 
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 90 days following the conference for those unable to listen live. About Ocera Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com. Contact:
Susan Sharpe
Ocera Therapeutics, Inc.
[email protected]
919-328-1109


Read more...
Ocera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 10, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced updates to its clinical development programs and reported financial results for the quarter and year ended December 31, 2016.
“2016 was a busy year for Ocera, culminating with the timely completion of enrollment in the fourth quarter of STOP-HE, a landmark study evaluating intravenous OCR-002 (ornithine phenylacetate) in patients hospitalized with acute hepatic encephalopathy (HE),” said Linda Grais, M.D., Chief Executive Officer of Ocera. “We also advanced our oral program testing orally-administered OCR-002 in patients with cirrhosis and developing a tablet formulation which is poised for clinical evaluation in 2017. “In January 2017, we reported positive results from our Phase 1 study of orally-administered OCR-002 in patients with chronic liver cirrhosis. The study demonstrated robust bioavailability and promising pharmacokinetic and safety profiles in the intended use population. In addition, we recently announced the data from STOP-HE, including encouraging results demonstrating that OCR-002 is a potent ammonia scavenger, that the level of HE severity directly correlates with the level of ammonia, and that ammonia reduction correlates with clinical improvement in HE symptoms. Recent analyses support our belief that OCR-002 can become an important intervention in both the treatment and prevention of HE,” added Dr. Grais. Anticipated 2017 Activity Initiate Phase 2a multi-dose study of oral OCR-002 in cirrhotic patients in H1 2017Meet with the Food and Drug Administration in Q3 2017 regarding STOP-HE with goal of clarifying Phase 3 development plan Fourth Quarter and Full Year 2016 Financial Results As of December 31, 2016, Ocera had cash, cash equivalents and investments of $28.4 million, compared with $43.3 million at December 31, 2015. Net use of cash for 2016 was $22.1 million, which was consistent with Ocera’s most recent guidance of the low end of the range of $22.0 to $26.0 million. Net use of cash equals the difference of cash, cash equivalents and investments at December 31, 2016 and 2015, less cash provided by financing activities, consisting of net proceeds of $7.1 million generated by an “At-the-Market” equity program during 2016. Net loss for the three and twelve months ended December 31, 2016 was $5.2 million and $26.9 million, respectively. Net loss for the three and twelve months ended December 31, 2015 was $7.1 million and $26.5 million, respectively. Basic and diluted net loss per share for the three and twelve months ended December 31, 2016 was $0.22 and $1.22, respectively. Basic and diluted net loss per share for the three and twelve months ended December 31, 2015 was $0.34 and $1.32, respectively. Revenue for the three and twelve months ended December 31, 2016 was $512,000 and $609,000, respectively. Revenue for the three and twelve months ended December 31, 2015 was $24,000 and $133,000, respectively. Revenue in all periods consisted of royalty and licensing revenue generated from certain clinical-stage assets acquired in connection with the 2013 reverse merger between Ocera and Tranzyme, Inc. Research and development (R&D) expense for the three and twelve months ended December 31, 2016 was $3.2 million and $16.1 million, respectively. R&D expense for the three and twelve months ended December 31, 2015 was $3.9 million and $16.0 million, respectively. The decrease in R&D expense for the three-month period was due primarily to a decrease in external development expenses, partially offset by personnel and related expenses. General and administrative (G&A) expense for the three and twelve months ended December 31, 2016 was $2.2 million and $10.4 million, respectively. G&A expense for the three and twelve months ended December 31, 2015 was $2.9 million and $10.3 million, respectively. The decrease in G&A expense for the three-month period was due primarily to lower personnel and related expenses. Financial Guidance Ocera anticipates it will have sufficient cash to fund operations into the second quarter of 2018 based on its current operating plan and re-prioritization of certain development activities. About Ocera Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com. Forward-Looking Statements This press release contains "forward-looking" statements, including, without limitation, all statements related to the OCR-002 clinical development program, including but not limited to the potential benefits of OCR-002 to help patients with hepatic encephalopathy, the timing of our planned meeting with the FDA, our ability to identify a development path forward for OCR-002, whether any future studies of OCR-002 we may conduct will demonstrate similar results to our Phase 2b study, the timing of our planned Phase 2a study of the oral formulation of OCR-002 in cirrhotic patients, the timing and nature of our future clinical development plans, and the company’s financial projections. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "expected," "hope," "plan," "potential," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ocera's current expectations. Forward-looking statements involve risks and uncertainties and Ocera's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that we may need to conduct one or more additional studies in light of the fact our Phase 2b trial did not meet its clinical endpoints, including related cost and timing issues associated with future studies, if any, our ability to raise sufficient capital or consummate other strategic transactions to enable the continued development of OCR-002 and those risks and uncertainties discussed under the heading "Risk Factors" in Ocera's Annual Report on Form 10-K for the year ended December 31, 2015 and subsequent filings with the SEC. All information in this press release is as of the date of the release, and Ocera undertakes no duty to update this information unless required by law. Susan Sharpe
Ocera Therapeutics, Inc.
[email protected]
919-328-1109 Ocera Therapeutics, Inc.        Condensed Consolidated Statement of Operations        (Unaudited)        (In thousands, except per share data)                  Three Months Ended December 31, Twelve Months Ended December 31,   2016   2015   2016   2015  Revenues:        Royalty and licensing revenues$512  $24  $609  $133  Operating expenses:        Research and development 3,186   3,927   16,125   15,977  General and administrative 2,222   2,861   10,364   10,321  Amortization of intangibles -   48   -   171  Total operating expenses 5,408   6,836   26,489   26,469  Loss from operations (4,896)  (6,812)  (25,880)  (26,336) Net interest income (expense) (257)  (272)  (1,015)  (413) Net loss from continuing operations (5,153)  (7,084)  (26,895)  (26,749) Net income from discontinued operations -   8   -   227  Net loss$(5,153) $(7,076) $(26,895) $(26,522)  Net loss per share from continuing operations, basic and diluted$(0.22) $(0.34) $(1.22) $(1.33) Net income per share from discontinued operations, basic and diluted -   -   -   0.01  Net loss per share, basic and diluted$(0.22) $(0.34) $(1.22) $(1.32) Shares used to compute net loss per share, basic and diluted 23,223,569   20,556,822   21,957,917   20,067,660   Ocera Therapeutics, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands)                  December 31,  December 31,        2016   2015               Cash, cash equivalents and marketable securities$28,360  $43,336      Working capital, excluding notes payable 24,890   40,188      Total assets 29,639   44,737      Notes payable 9,703   9,508      Accumulated deficit (158,328)  (131,433)     Total stockholders' equity$15,737  $31,394           


Read more...
Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy

IV OCR-002 statistically significantly normalized ammonia faster than standard of care Ammonia reduction statistically significantly correlated with clinical improvement in HE symptoms Ocera plans to meet with FDA in Q3 2017 to inform development paths forward for IV OCR-002 Company presentation scheduled for today, March 8, 2017 at 11:20 AM ET PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 08, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced it will report additional encouraging results from its Phase 2b STOP-HE study of intravenous (IV) OCR-002 in hospitalized patients with Hepatic Encephalopathy (HE) at the Cowen and Company 37th Annual Healthcare Conference at 11:20 AM Eastern Time today. "Further analysis of the data from our STOP-HE trial confirms that OCR-002 rapidly and safely lowered ammonia and, importantly, the ammonia reduction correlated statistically with clinical improvement," said Linda Grais, M.D., Chief Executive Officer of Ocera. "With greater confidence, we believe the most relevant efficacy considerations likely include earlier timing of drug administration, measuring efficacy sooner after drug administration, and administering the appropriate and tolerable dose regimen of OCR-002. We look forward to discussing these data as well as Phase 3 development with FDA later this year." “We are very encouraged by the additional study data indicating IV OCR-002 provided clinical benefit over placebo in other parameters as well, such as the Physician Overall Evaluation, Model for End-Stage Liver Disease (MELD) scores, and in renal function as measured by the change from baseline in Blood Urea Nitrogen (BUN) levels,” said Stan Bukofzer, M.D., Chief Medical Officer of Ocera. Initial STOP-HE results reported in January 2017 included:
OCR-002 demonstrated a highly statistically significant reduction in ammonia levels over placebo, p=0.028;Higher doses (15g, 20g) showed strong evidence of benefit across multiple endpoints;Clinical improvement dose trend observed; responder rate increased as dose increased and was superior to placebo at all doses; andOCR-002 was safe and well-tolerated; higher doses had a lower percentage of deaths and life threatening adverse events compared to placebo           Additional results to be presented today include: Ammonia reduction correlates with clinical improvement, p=0.0006;Dose proportional response and pharmacokinetic data indicate some patients were under-dosed;Earlier timing of drug administration and efficacy assessment is important:
- Patients who improve within 48 hours are discharged earlier than patients who do not improve within 48 hours;
- Patients on OCR-002 are more likely to respond within 48 hours compared to placebo, p=0.026;Pre-defined measures of improvement were statistically significant: ammonia reduction, p=0.017 and Physician overall evaluation, p= 0.026;OCR-002 demonstrated improvement in the Model for End-Stage Liver Disease (MELD) scores, p=0.051; andOCR-002 showed improvement in renal function as measured by the change from baseline in Blood Urea Nitrogen (BUN) levels, p=0.04 A live webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 60 days following the conference for those unable to listen live.
STOP-HE Study Design STOP-HE was a placebo-controlled, randomized, double-blind clinical trial designed to evaluate the safety, pharmacokinetics and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in 231 hospitalized patients with liver cirrhosis and elevated serum ammonia (hyperammonemia). Either OCR-002 or placebo was administered to patients intravenously as a continuous infusion for up to five days along with standard of care. The OCR-002 arm was dosed with 10, 15 or 20 grams over 24 hours based on the patient's degree of liver impairment and modeling of OCR-002 metabolism, in addition to safety considerations in this high-risk patient population.

About Hepatic Encephalopathy Hepatic encephalopathy (HE) is a debilitating and progressive complication of liver cirrhosis or liver failure, marked by increasing ammonia levels, mental changes including confusion, impaired motor skills, disorientation, and in its more severe form, stupor, coma and even death. HE is categorized as either covert or overt depending on the degree of neurocognitive impairment, with overt HE (OHE) typically precipitating the need for hospitalization. Patients frequently cycle from remission to recurrence following an initial overt episode. The number of OHE episodes appears to be directly linked to persistent neurological impairment and seems to be cumulative; thus the need to manage HE patients is vital. It is estimated that HE-related hospitalization costs exceed $7 billion1 annually in the U.S. alone. 1 Clinical Gastroenterology and Hepatology 2012; 10:1034-1041 About Ocera Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. Ocera's HE clinical development efforts also include a recently completed Phase 1 clinical trial of an oral formulation of OCR-002 in patients with cirrhosis as a potential chronic use option to maintain remission of HE. The Company expects to initiate a multi-dose Phase 2a study of oral OCR-002, also in cirrhotic patients, in the first half of 2017. For additional information, please see www.ocerainc.com. Forward-Looking Statements This press release contains "forward-looking" statements, including, without limitation, all statements related to the OCR-002 clinical development program, including but not limited to the potential benefits of OCR-002 to help patients with hepatic encephalopathy, the timing of our planned meeting with the FDA, our ability to identify a development path forward for OCR-002, whether any future studies of OCR-002 we may conduct will demonstrate similar results to our Phase 2b study, the timing of our planned Phase 2a study of the oral formulation of OCR-002 in cirrhotic patients, and the timing and nature of our future clinical development plans. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "expected," "hope," "plan," "potential," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ocera's current expectations. Forward-looking statements involve risks and uncertainties and Ocera's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that we may need to conduct one or more additional studies in light of the fact our Phase 2b trial did not meet its clinical endpoints, including related cost and timing issues associated with future studies, if any, our ability to raise sufficient capital or consummate other strategic transactions to enable the continued development of OCR-002, as well as those risks and uncertainties discussed under the heading "Risk Factors" in Ocera's Annual Report on Form 10-K for the year ended December 31, 2015 and subsequent filings with the SEC. All information in this press release is as of the date of the release, and Ocera undertakes no duty to update this information unless required by law. OCRX-G Susan Sharpe
Ocera Therapeutics, Inc.
[email protected] 
919-328-1109


Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.27
OCRX's PB Ratio is ranked higher than
76% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. OCRX: 2.27 )
Ranked among companies with meaningful PB Ratio only.
OCRX' s PB Ratio Range Over the Past 10 Years
Min: 0.88  Med: 2.45 Max: 10.5
Current: 2.27
0.88
10.5
PS Ratio 47.20
OCRX's PS Ratio is ranked lower than
74% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. OCRX: 47.20 )
Ranked among companies with meaningful PS Ratio only.
OCRX' s PS Ratio Range Over the Past 10 Years
Min: 0.06  Med: 213.89 Max: 3600
Current: 47.2
0.06
3600
Current Ratio 1.98
OCRX's Current Ratio is ranked lower than
75% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. OCRX: 1.98 )
Ranked among companies with meaningful Current Ratio only.
OCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.62  Med: 5.34 Max: 21.99
Current: 1.98
0.62
21.99
Quick Ratio 1.98
OCRX's Quick Ratio is ranked lower than
70% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. OCRX: 1.98 )
Ranked among companies with meaningful Quick Ratio only.
OCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 5.34 Max: 21.99
Current: 1.98
0.62
21.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.70
OCRX's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. OCRX: -15.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -983.2  Med: -61.85 Max: 0
Current: -15.7
-983.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.51
OCRX's Price-to-Net-Cash is ranked higher than
85% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. OCRX: 2.51 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OCRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.54  Med: 2.84 Max: 10.42
Current: 2.51
1.54
10.42
Price-to-Net-Current-Asset-Value 2.36
OCRX's Price-to-Net-Current-Asset-Value is ranked higher than
86% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. OCRX: 2.36 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OCRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.35  Med: 2.77 Max: 8.97
Current: 2.36
1.35
8.97
Price-to-Tangible-Book 2.36
OCRX's Price-to-Tangible-Book is ranked higher than
79% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. OCRX: 2.36 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OCRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.24  Med: 2.63 Max: 7.99
Current: 2.36
1.24
7.99
Price-to-Median-PS-Value 0.22
OCRX's Price-to-Median-PS-Value is ranked higher than
92% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. OCRX: 0.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OCRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 1.35 Max: 13.23
Current: 0.22
0.01
13.23
Earnings Yield (Greenblatt) % -164.22
OCRX's Earnings Yield (Greenblatt) % is ranked lower than
96% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. OCRX: -164.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OCRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -354  Med: -45.2 Max: 1821
Current: -164.22
-354
1821

More Statistics

Revenue (TTM) (Mil) $0.61
EPS (TTM) $ -1.14
Beta1.54
Short Percentage of Float5.89%
52-Week Range $0.52 - 3.15
Shares Outstanding (Mil)26.51

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -0.93 -0.95 -1.01
EPS without NRI ($) -0.93 -0.95 -1.01
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OCRX

Headlines

Articles On GuruFocus.com
Pandora CEO, 2 Other Officers Resign Jun 28 2017 
Patterson-UTI Energy Is Interesting Post-Correction Jun 28 2017 
Correction Is an Opportunity to Accumulate Dorian LPG Jun 28 2017 
Charlie Tian's Interview on The Next Level Show Jun 28 2017 
Foot Locker Is the Hidden Gem of Retail Jun 28 2017 
Seeking Value in the Grocery Aisle Jun 28 2017 
Seeking Value in Bermuda: Everest Re Group Jun 28 2017 
Paulson Dives Deeper Into Valeant With Increased Holding Jun 27 2017 
US Market Indexes Lower, Technology Stock Volatility a Factor Jun 27 2017 
General Mills to Release 4th-Quarter, Full-Fiscal 2017 Results Jun 27 2017 

More From Other Websites
Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis Jun 01 2017
Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of... May 26 2017
Edited Transcript of OCRX earnings conference call or presentation 9-May-17 8:30pm GMT May 16 2017
Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update May 09 2017
Investor Network: Ocera Therapeutics, Inc. to Host Earnings Call May 09 2017
ETFs with exposure to Ocera Therapeutics, Inc. : May 3, 2017 May 03 2017
Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May... May 03 2017
Today's Research Reports on Biotech Stocks to Watch: Ocera Therapeutics and Verastem Apr 17 2017
Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis... Apr 12 2017
ETFs with exposure to Ocera Therapeutics, Inc. : April 7, 2017 Apr 07 2017
Ocera Therapeutics, Inc. :OCRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
Ocera Therapeutics, Inc. :OCRX-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Mar 16 2017
Here’s What’s Moving Immunomedics, Inc. (IMMU) And Ocera Therapeutics Inc (OCRX) Mar 10 2017
Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Ocera... Mar 09 2017
Five Penny Stocks to Buy Now Mar 07 2017
Lifshitz & Miller LLP Announces Investigation of Centrue Financial Corporation, Motorola Solutions,... Feb 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}